These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31299074)

  • 1. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    Neary M; Chappell CA; Scarsi KK; Nakalema S; Matovu J; Achilles SL; Chen BA; Siccardi M; Owen A; Lamorde M
    J Antimicrob Chemother; 2019 Oct; 74(10):3003-3010. PubMed ID: 31299074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Neary M; Lamorde M; Olagunju A; Darin KM; Merry C; Byakika-Kibwika P; Back DJ; Siccardi M; Owen A; Scarsi KK
    Clin Pharmacol Ther; 2017 Sep; 102(3):529-536. PubMed ID: 28187506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
    Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of double vs single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Kyohairwe I; Byakika-Kibwika P; Meyn LA; Pham MM; Scarsi KK
    Am J Obstet Gynecol; 2024 Aug; 231(2):242.e1-242.e9. PubMed ID: 38458408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
    Patel RC; Stalter RM; Thomas KK; Tamraz B; Blue SW; Erikson DW; Kim CJ; Kelly EJ; Nanda K; Kourtis AP; Lingappa JR; Mugo N; Baeten JM; Scarsi KK;
    AIDS; 2019 Nov; 33(13):1995-2004. PubMed ID: 31306173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
    Vieira CS; Bahamondes MV; de Souza RM; Brito MB; Rocha Prandini TR; Amaral E; Bahamondes L; Duarte G; Quintana SM; Scaranari C; Ferriani RA
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):378-85. PubMed ID: 24798768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
    Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
    Stalter RM; Amorim G; Mocello AR; Jakait B; Shepherd BE; Musick B; Bernard C; Bukusi EA; Wools-Kaloustian K; Cohen CR; Yiannoutsos CT; Patel RC;
    J Int AIDS Soc; 2022 Sep; 25(9):e26001. PubMed ID: 36073977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK
    AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.
    Bishop IJ; Gertz AM; Simon B; Tawe L; Lechiile K; Liu S; Teodoro N; Mussa A; Avalos A; Malima S; Maotwe T; Mokganya L; Westhoff CL; Morroni C
    Contraception; 2020 Sep; 102(3):174-179. PubMed ID: 32387328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
    Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
    Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
    Čolić A; Alessandrini M; Pepper MS
    Drug Metab Rev; 2015 May; 47(2):111-23. PubMed ID: 25391641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
    Abdissa A; Olsen MF; Yilma D; Tesfaye M; Girma T; Christiansen M; Hagen CM; Wiesner L; Castel S; Aseffa A; McIlleron H; Pedersen C; Friis H; Andersen AB
    HIV Med; 2015 Aug; 16(7):403-11. PubMed ID: 25974723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
    Ragazini CS; Bahamondes MV; Prandini TR; Brito MB; Amaral E; Bahamondes L; Duarte G; Quintana SM; Ferriani RA; Vieira CS
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):285-9. PubMed ID: 27227739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
    Kreitchmann R; Stek A; Best BM; Capparelli E; Wang J; Shapiro D; Chakhtoura N; Mirochnick M; Eke AC;
    Contraception; 2022 Jan; 105():67-74. PubMed ID: 34407424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.